Tonix Pharmaceuticals Holding Forum: Community User: StefanN19

Sie schließen sie gern

Tonix Pharmaceuticals to Present at Biotech Showcase 2020 January 07, 2020 07:00 ET | Source: Tonix Pharmaceuticals Holding Corp. NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present and conduct investor meetings at Biotech Showcase 2020 being held January 13-15, 2020 at the Hilton San Francisco Union Square. Details of the Tonix Pharmaceuticals presentation and webcast are as follows: Event: Biotech Showcase 2020 Date: Tuesday, January 14, 2020 Time: 10:00 a.m. PT (1:00 p.m. ET) Location: Hilton San Francisco Union Square, San Francisco Track Franciscan A (Ballroom Level) A live webcast and subsequent archived recording of the Company presentation will be available under the IR Events tab of the Investors section of the Tonix Pharmaceuticals website at www.tonixpharma.com. About Tonix Pharmaceuticals Holding Corp. Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions. Tonix’s lead product candidate, TNX-102 SL*, is in development for posttraumatic stress disorder (PTSD), fibromyalgia, agitation in Alzheimer’s disease and alcohol use disorder (AUD). TNX-102 SL is in Phase 3 development as a bedtime treatment for PTSD (trade name Tonmya**) and fibromyalgia. The Phase 3 RECOVERY trial (P302) in PTSD is currently enrolling and results from an interim analysis are expected in the first quarter of 2020 and topline data are expected in the second quarter of 2020 if the sample size remains the same. The Company has started enrollment in the Phase 3 RELIEF trial in fibromyalgia and expects to report results from an interim analysis in the second half of 2020. The agitation in Alzheimer’s disease program is Phase 2 ready and the development for AUD is in the pre-Investigational New Drug (IND) application stage. TNX-601 CR (tianeptine oxalate controlled-release tablets) is in development as a daytime treatment for depression, as well as for PTSD. The first efficacy study will be performed outside the U.S. and it is expected to be IND-ready in 2020. TNX-1600 (a triple reuptake inhibitor) is a third product candidate being developed for PTSD, as a daytime treatment. Tonix‘s programs for treating addiction conditions also include TNX-1300*** (double-*** cocaine esterase), which is in Phase 2 development for the treatment of cocaine intoxication. Tonix’s preclinical pipeline includes TNX-1500 (anti-CD154), a monoclonal antibody being developed to prevent and treat organ transplant rejection and autoimmune conditions, and TNX-1700 (rTFF2), a biologic being developed to treat gastric and pancreatic cancers. Finally, TNX-801 (live virus vaccine for percutaneous [scarification] administration) to potentially prevent smallpox and TNX-701 (undisclosed small molecule) to prevent radiation effects are being advanced as medical countermeasures to improve biodefense. *TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an investigational new drug and has not been approved for any indication. **Tonmya has been conditionally accepted by the U.S. Food and Drug Administration (FDA) as the proposed trade name for TNX-102 SL for the treatment of PTSD. ***TNX-1300 (T172R/G173Q double-*** cocaine esterase 200 mg, i.v. solution) is an investigational new biologic and has not been approved for any indication. This press release and further information about Tonix can be found at www.tonixpharma.com. Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2019, and periodic reports on Form 10-Q filed with the SEC on or after the date thereof. Tonix does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Contacts Jessica Morris (corporate) Tonix Pharmaceuticals investor.relations@tonixpharma.com (212) 980-9159 Scott Stachowiak (media) Russo Partners scott.stachowiak@russopartnersllc.com (646) 942-5630 Peter Vozzo (investors) Westwicke peter.vozzo@westwicke.com (443) 213-0505 Related Articles More articles issued by Tonix Pharmaceuticals Holding Corp. More articles related to: Calendar of Events Health

Dachte die 2 halt

Schade

Gekommen um zu bleiben. Meeega! 😃

Bin auch drin

Ja, 💪

Ich bleibe auch 💪🏾

Sehr schön ☺

Na dann bleib ich doch auch Leute. Zusammen ist es doch immer am schönsten 🍻👍

Bleib auch

Das ist erst der Anfang!😉

Schade , ist wieder runter gefallen. Mal schauen was noch so passiert. Bleibt ihr dabei oder verkauft jemand ?

NEW YORK, 07. Januar 2020 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix oder das Unternehmen) gab heute bekannt, dass Dr. Seth Lederman, President und Chief Executive Officer von Tonix, Anlegerversammlungen präsentieren und durchführen wird auf der Biotech Showcase 2020 vom 13. bis 15. Januar 2020 im Hilton San Francisco Union Square.

Kommen news oder einfach nur Gap close ?

La.chs